Disease block
C43-C44 – Melanom und sonstige bösartige Neubildungen der Haut
- Chapter II: Neubildungen
37Decisions
56Patient groups
Added benefit by patient group
- Considerable11
- Minor2
- Non-quantifiable4
- Not proven37
- Lesser benefit2
Diseases in this disease block
- C43 Bösartiges Melanom der Haut 30 decisions
- C44 Sonstige bösartige Neubildungen der Haut 12 decisions
Decisions, newest first
Each decision lists only the patient groups coded with a disease in this disease block.
- 2026-10-01ZynyzRetifanlimabNon-quantifiable
- 2026-06-04LibtayoCemiplimabNon-quantifiable
- 2025-10-16AugtyroRepotrectinibNot proven: 2 of 2 patient groups
- 2024-11-07RetsevmoSelpercatinibNot proven
- 2024-03-21OpdivoNivolumabNot proven
- 2024-02-06RozlytrekEntrectinibNot proven
- 2023-12-21OpdivoNivolumabNot proven
- 2023-12-21OpdivoNivolumabNot proven: 2 of 2 patient groups
- 2023-01-19KeytrudaPembrolizumabNot proven
- 2023-01-19KeytrudaPembrolizumabNon-quantifiable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2022-01-20LibtayoCemiplimabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2021-09-16OpdivoNivolumabConsiderable
- 2021-02-18RozlytrekEntrectinibNot proven
- 2020-10-01BavencioAvelumabNot proven
- 2020-04-02VitrakviLarotrectinibNot proven
- 2020-02-06LibtayoCemiplimabNot proven: 2 of 2 patient groups
- 2019-09-19KeytrudaPembrolizumabNon-quantifiable
- 2019-03-22BraftoviEncorafenibNot proven: 2 of 2 patient groups
- 2019-03-22MektoviBinimetinibNot proven: 2 of 2 patient groups
- 2019-03-22MekinistTrametinibConsiderable
- 2019-03-22TafinlarDabrafenibConsiderable
- 2018-12-20YervoyIpilimumabNot proven: 2 of 3 patient groupsLesser benefit: 1 of 3 patient groups
- 2018-12-20OpdivoNivolumabLesser benefit
- 2018-08-02YervoyIpilimumabNot proven
- 2018-08-02OdomzoSonidegibNot proven
- 2016-12-15OpdivoNivolumabNot proven: 2 of 2 patient groups
- 2016-12-15ImlygicTalimogen laherparepvecNot proven: 3 of 3 patient groups
- 2016-08-04ErivedgeVismodegibMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-06-02CotellicCobimetinibConsiderable
- 2016-03-17MekinistTrametinibConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-03-17TafinlarDabrafenibConsiderable
- 2016-02-04KeytrudaPembrolizumabConsiderable: 2 of 3 patient groupsNot proven: 1 of 3 patient groups
- 2016-01-07OpdivoNivolumabConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2014-06-05YervoyIpilimumabNot proven: 2 of 2 patient groups
- 2014-04-03TafinlarDabrafenibNot proven
- 2014-03-06ZelborafVemurafenibConsiderable
- 2012-08-02YervoyIpilimumabConsiderable
Data status: 2026-10-29